Referencias bibliográficas

  1. Siegel R. et al., Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
  2. Hulka BS and Moorman PG. Breast cancer: hormones and other risk factors. Maturitas. 2001;38:103–116.
  3. Carr BR. et al., The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum. Fertil Steril. 19823;38:03–311.
  4. Melmed S. et al., Textbook of Endocrinology. 12. Philadelphia, PA: Saunders press; 2011. pp. 599–602.
  5. Ryan J. Biological aromatization of steroids. J Biol Chem. 1959;234:268–272.
  6. Simpson ER. et al., Aromatases: a brief overview. Annu Rev Physiol. 2002;64:93–127.
  7. Tsuchiya Y. et al., Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115–124.
  8. Raftogianis R. et al., Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr. 2000;27:113–124.
  9. Huang Z. et al., Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 19968;24:99–905.
  10. van Aswegen CH. et al., Binding of 2-hydroxyestradiol and 4-hydroxyestrdiol to estrogen receptor human breast cancers. J Steroid Biochem. 1989;32:485–492.
  11. Bradlow HL. et al., 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996;150:S259–S265.
  12. Liehr JG. and Ricci MJ. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA. 1996;93:3294–6.
  13. Osborne MP. et al., Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst. 1993;85:1917–20.
  14. Parl FF. Estrogens, estrogen receptor and breast cancer. IOS Press; Amsterdam: 2000. Estrogen receptor expression in breast cancer; pp. 135–204.
  15. Trichopoulos D. et al., Menopause and breast cancer risk. J Natl Cancer Inst. 1972;48:605–13.
  16. Gordon GB. et al., Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res. 1990;50:3859–62.
  17. Key T. et al., Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–16.
  18. Licznerska B. et al., Modulating potential of L-sulforaphane in the expression of cytochrome p450 to identify potential targets for breast cancer chemoprevention and therapy using breast cell lines. Phytother Res. 2015 Jan;29(1):93-9.
  19. Cortes M. and Singletary K. Regulation of estrogen receptor alpha expression in human breast cancer cells by sulforaphane. J Nutr Biochem. 2009 Mar;20(3):195-201.
  20. Russo M. et al., Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment. Crit Rev Food Sci Nutr. 2018 May 24;58(8):1391-1405.
  21. Dawood HM. et al., Integrated in silico-in vitro strategy for screening of some traditional Egyptian plants for human aromatase inhibitors. J Ethnopharmacol. 2018 Oct 5:224:359-372.
  22. Shun H. et al., Cytotoxic effects of Vitex agnuscastus fruit extract against human cultured uterine cervical fibroblast, breast cancer and ovarian cancer cells, and its biochemical mechanism. Acta Hortic. 2003, 597, 167-176.
  23. van Die MD. et al., Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013 May;79(7):562-75.
  24. Arentz S. et al., Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014 Dec 18:14:511.
  25. Nasiadek M. et al., The Role of Zinc in Selected Female Reproductive System Disorders. Nutrients. 2020 Aug 16;12(8):2464.